Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Genasense: GNTA and partner Aventis S.A. (AVE, Strasbourg, France) decided to increase the size of the Phase III melanoma trial from 450 to 750 patients. GNTA s

Genta Inc. (GNTA), Berkeley Heights, N.J.
Product: Genasense
Business: Cancer
Therapeutic category: Apoptosis, Antisense
Target: Bcl-2

Read the full 163 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE